

Tegaserod (Zelnorm[®] — Novartis)

References

1. Viera A, Hoag S, Shaughnessy J. Management of irritable bowel syndrome. *Am Fam Physician.* 2002;66:1867-1874.
2. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based positions statement on the management of irritable bowel syndrome in North America. *Am J Gastroenterol.* 2002;111Suppl:S1-S5.
3. Camilleri M. Management of the irritable bowel syndrome. *Gastroenterology.* 2001;120:652-668.
4. Talley NJ. Serotonergic neuroenteric modulators. *Lancet.* 2001;358:2061-2068.
5. Kamm MA. Review article: the complexity of drug development for irritable bowel syndrome. *Aliment Pharmacol Ther.* 2002;16:343-351.
6. Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. *Am J Gastroenterol.* 2002;97:2321-2327.
7. Product information. Zelnorm[®] (tegaserod maleate). Novartis Pharmaceuticals, Corp. East Hanover, NJ. 2002.
8. Appel S, Kumle A, Meier R. Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT₄ receptor agonist, in a model of slow colonic transit. *Clin Pharmacol Ther.* 197;62:546-555.
9. Camilleri M. Review article: tegaserod. *Aliment Pharmacol Ther.* 2001;15:277-289.
10. Appel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT₄ receptor partial agonist with promotile activity. *Clin Pharmacokinet.* 2002;41:1021-1042.
11. Appel-Dingemanse S, Horowitz A, Campestrini J, Osborne S, McLeod J. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects – male and female, elderly and young. *Aliment Pharmacol Ther.* 2001;15:937-944.
12. Novartis Pharmaceuticals Corporation. *ZelmacTM(tegaserod) Advisory Committee Briefing Document.* May 24, 2000. Novartis Pharmaceuticals Corporation. East Hanover, NJ. Available at: <http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf>. Accessed April 3, 2003.
13. Muller-Lissner A, Fumagalli I, Bardhan KD, Pace F, Pecher E. Tegaserod, a 5-HT₄ receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation. *Aliment Pharmacol Ther.* 2001;15:1655-1666.
14. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. *Aliment Pharmacol Ther.* 2002;16:1877-1888.
15. Tougas G, Snape WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation predominant irritable bowel syndrome. *Aliment Pharmacol Ther.* 2002;16:1701-1708.
16. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther.* 2000;14:1503-1509.

17. Food and Drug Administration Center for Drug Evaluation and Research. *Zelnorm (Tegaserod Maleate) Tablets. Administrative document(s): part II.* Available at: http://www.fda.gov/cder/foi/nda/2002/21-200_Zelnorm.htm. Accessed April 5, 2003.